Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) (NCT04197596)
A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients
🩺 Plain-English Summary (8th-Grade Level)
BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco — San Francisco, California
Age range: 1 Month to 79 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- University of California San Francisco — San Francisco, California
- Johns Hopkins — Baltimore, Maryland
- Washington University — St Louis, Missouri
- New York Medical College — Vallhala, New York
- Nationwide Children's Hosptial — Columbus, Ohio
- Children's Hospital of Pennsylvania — Philadelphia, Pennsylvania
- Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (914) 594-2150
Email: mitchell_cairo@nymc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Viral Infection
- Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis — Washington D.C., District of Columbia
- Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts — Washington D.C., District of Columbia
- Third Party Viral Specific T-cells (VSTs) — Akron, Ohio
- School Inner City Air Study — Boston, Massachusetts
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. — Houston, Texas
Explore by condition: All Viral Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.